VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q42430887 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000131.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q42430887‏
024 ‎‡a 0000-0002-6692-6186‏ ‎‡2 orcid‏
024 ‎‡a 35517147900‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q42430887‏
100 0 ‎‡a Francesc Vidal‏ ‎‡9 ast‏ ‎‡9 es‏ ‎‡9 sl‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Francesc Vidal‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Francesc Vidal‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz‏
670 ‎‡a Author's A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of ART in HIV-infected patients.‏
670 ‎‡a Author's A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects.‏
670 ‎‡a Author's A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients‏
670 ‎‡a Author's A study of fatty acid binding protein 4 in HIV-1 infection and in combination antiretroviral therapy-related metabolic disturbances and lipodystrophy‏
670 ‎‡a Author's A study on the TNF-α system in Caucasian Spanish patients with alcoholic liver disease‏
670 ‎‡a Author's Absence of CXCR4 C-terminal polymorphisms in HIV-1-infected and uninfected Spaniards.‏
670 ‎‡a Author's Adipogenic/Lipid, Inflammatory, and Mitochondrial Parameters in Subcutaneous Adipose Tissue of Untreated HIV-1–Infected Long-Term Nonprogressors‏
670 ‎‡a Author's Alcohol dehydrogenase of human and rat blood vessels. Role in ethanol metabolism.‏
670 ‎‡a Author's An unusual presentation of secondary pleural hydatidosis‏
670 ‎‡a Author's An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes‏
670 ‎‡a Author's Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.‏
670 ‎‡a Author's ART regimes and fat: the healing hand wielding the sword.‏
670 ‎‡a Author's Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.‏
670 ‎‡a Author's Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain.‏
670 ‎‡a Author's Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy‏
670 ‎‡a Author's Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapy‏
670 ‎‡a Author's Atazanavir dose reduction: one size does not fit all.‏
670 ‎‡a Author's Atypical liver alcohol dehydrogenase in the Spanish population: its relation with the development of alcoholic liver disease‏
670 ‎‡a Author's Bacteraemia in adults due to glucose non-fermentative Gram-negative bacilli other than P. aeruginosa‏
670 ‎‡a Author's Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy‏
670 ‎‡a Author's Características clínicas y evolución de la endocarditis infecciosa en una población general no seleccionada, atendida en un hospital docente que no dispone de cirugía cardiaca. Estudio de 120 casos‏
670 ‎‡a Author's Central Nervous System Pneumocystosis in AIDS: Antemortem Diagnosis and Successful Treatment‏
670 ‎‡a Author's Cerebral Pneumocystis carinii infection in AIDS.‏
670 ‎‡a Author's Characteristics and outcome of HIV infection in gypsies in the Spanish VACH Cohort‏
670 ‎‡a Author's Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients‏
670 ‎‡a Author's Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy‏
670 ‎‡a Author's Clinical characterization of breakthrough bacteraemia: a survey of 392 episodes.‏
670 ‎‡a Author's Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort‏
670 ‎‡a Author's Combination antiretroviral therapy.‏
670 ‎‡a Author's Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients‏
670 ‎‡a Author's Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.‏
670 ‎‡a Author's Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients‏
670 ‎‡a Author's Cutaneous polyarteritis nodosa in human immunodeficiency virus infection.‏
670 ‎‡a Author's Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.‏
670 ‎‡a Author's Diagnosis of hepatic hydrothorax in the absence of ascites by intraperitoneal injection of 99m-Tc-Fluor colloid‏
670 ‎‡a Author's Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients.‏
670 ‎‡a Author's Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease?‏
670 ‎‡a Author's Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection‏
670 ‎‡a Author's Drug safety profile of integrase strand transfer inhibitors.‏
670 ‎‡a Author's Drug therapies for HIV-related metabolic disorders.‏
670 ‎‡a Author's Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.‏
670 ‎‡a Author's Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects.‏
670 ‎‡a Author's Effect of TNF- Alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards‏
670 ‎‡a Author's Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort‏
670 ‎‡a Author's Effects of docosahexanoic acid on metabolic and fat parameters in HIV-infected patients on cART: A randomized, double-blind, placebo-controlled study‏
670 ‎‡a Author's Effects of docosahexanoic acid supplementation on inflammatory and subcutaneous adipose tissue gene expression in HIV-infected patients on combination antiretroviral therapy (cART). A sub-study of a randomized, double-blind, placebo-controlled study‏
670 ‎‡a Author's Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.‏
670 ‎‡a Author's Epidemiology and clinical manifestations of infection due to Nocardia species in Tarragona, 1997-2008: Nocardia cyriacigeorgica is an emerging pathogen‏
670 ‎‡a Author's Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes‏
670 ‎‡a Author's Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients‏
670 ‎‡a Author's Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).‏
670 ‎‡a Author's Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.‏
670 ‎‡a Author's First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort‏
670 ‎‡a Author's Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemia‏
670 ‎‡a Author's Genetic polymorphisms of ADH2, ADH3, CYP4502E1 Dra-I and Pst-I, and ALDH2 in Spanish men: lack of association with alcoholism and alcoholic liver disease.‏
670 ‎‡a Author's Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients‏
670 ‎‡a Author's HBV primary drug resistance in newly diagnosed HIV–HBV-coinfected individuals in Spain‏
670 ‎‡a Author's High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients‏
670 ‎‡a Author's Higher levels of IL-6, CD4 turnover and Treg frequency are already present before cART in HIV-infected subjects with later low CD4 recovery.‏
670 ‎‡a Author's HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels‏
670 ‎‡a Author's HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain‏
670 ‎‡a Author's HIV/antiretroviral therapy-related lipodystrophy syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma.‏
670 ‎‡a Author's HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation‏
670 ‎‡a Author's HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers‏
670 ‎‡a Author's IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals.‏
670 ‎‡a Author's Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance-Supercontrollers‏
670 ‎‡a Author's In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells‏
670 ‎‡a Author's Incidence and risk factors of AIDS-defining cancers in a cohort of HIV-positive adults: Importance of the definition of incident cases‏
670 ‎‡a Author's Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor associated hypercholesterolaemia.‏
670 ‎‡a Author's Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults‏
670 ‎‡a Author's Influence of chronic alcohol abuse and liver disease on hepatic aldehyde dehydrogenase activity‏
670 ‎‡a Author's Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome‏
670 ‎‡a Author's Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS).‏
670 ‎‡a Author's Lack of Association of SDF-1 3???A Variant Allele With Long-Term Nonprogressive HIV-1 Infection Is Extended Beyond 16 Years‏
670 ‎‡a Author's Leptin and adiponectin, but not IL18, are related with insulin resistance in treated HIV-1-infected patients with lipodystrophy‏
670 ‎‡a Author's Lipodystrophy and Insulin Resistance in Combination Antiretroviral Treated HIV-1–Infected Patients: Implication of Resistin‏
670 ‎‡a Author's LMNA messenger RNA expression in highly active antiretroviral therapy-treated HIV-positive patients‏
670 ‎‡a Author's Mitochondrial and apoptotic in vitro modelling of differential HIV-1 progression and antiretroviral toxicity‏
670 ‎‡a Author's More on Adult Spontaneous Pneumomediastinum‏
670 ‎‡a Author's More on unusual forms of meningococcal disease: septic polyarthritis‏
670 ‎‡a Author's No relationship between TNF-α genetic variants and combination antiretroviral therapy-related lipodystrophy syndrome in HIV type 1-infected patients: a case-control study and a meta-analysis‏
670 ‎‡a Author's No Relationship BetweenTNF-αGenetic Variants and Combination Antiretroviral Therapy-Related Lipodystrophy Syndrome in HIV Type 1-Infected Patients: A Case-Control Study and a Meta-Analysis‏
670 ‎‡a Author's Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy‏
670 ‎‡a Author's Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants‏
670 ‎‡a Author's Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.‏
670 ‎‡a Author's Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality‏
670 ‎‡a Author's Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years.‏
670 ‎‡a Author's Polymorphisms in the 3′ untranslated region of the fractalkine‏
670 ‎‡a Author's Polymorphisms in the 3′ untranslated region of the fractalkine (CX3CL1) gene and the risk of HIV-1 infection and disease progression‏
670 ‎‡a Author's Polymorphisms in the interleukin-10 gene promoter and the risk of alcoholism and alcoholic liver disease in Caucasian Spaniard men.‏
670 ‎‡a Author's Polymorphisms of alcohol-metabolizing enzymes and the risk for alcoholism and alcoholic liver disease in Caucasian Spanish women‏
670 ‎‡a Author's Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40∶01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients‏
670 ‎‡a Author's Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach‏
670 ‎‡a Author's Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.‏
670 ‎‡a Author's Proteomic Profile Associated with Loss of Spontaneous HIV-1 Elite Control‏
670 ‎‡a Author's Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?‏
670 ‎‡a Author's Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1.‏
670 ‎‡a Author's Pyomyositis due to Escherichia coli in a patient infected by HIV.‏
670 ‎‡a Author's Randomized trial comparing pegylated interferon Alpha -2b versus pegylated interferon Alpha -2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients‏
670 ‎‡a Author's Recurrent Pericarditis and Cardiac Tamponade in Rheumatoid Arthritis: Effectiveness of Colchicine‏
670 ‎‡a Author's Reduced levels of serum FGF19 and impaired expression of receptors for endocrine FGFs in adipose tissue from HIV-infected patients.‏
670 ‎‡a Author's Relationship between HIV/Highly active antiretroviral therapy‏
670 ‎‡a Author's Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens‏
670 ‎‡a Author's Risk Factors, CD4 Long-Term Evolution and Mortality of HIV-Infected Patients who Persistently Maintain Low CD4 Counts, Despite Virological Response to HAART‏
670 ‎‡a Author's Sarcoidosis presenting as multiple pulmonary nodules and nephrotic syndrome.‏
670 ‎‡a Author's Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients‏
670 ‎‡a Author's Spanish HIV-1-Infected Long-Term Nonprogressors of More Than 15 Years Have an Increased Frequency of the CX3CR1 249I Variant Allele‏
670 ‎‡a Author's Spermatozoa from normozoospermic fertile and infertile individuals convey a distinct miRNA cargo.‏
670 ‎‡a Author's Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS.‏
670 ‎‡a Author's Switching antiretroviral regimes for the treatment of HIV: safety implications‏
670 ‎‡a Author's T wave alternans associated with amiodarone‏
670 ‎‡a Author's The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromes‏
670 ‎‡a Author's The relationship between antiretroviral prescription patterns and treatment guidelines in treatment-naïve HIV-1-infected patients‏
670 ‎‡a Author's The toxicogenetics of antiretroviral therapy: the evil inside‏
670 ‎‡a Author's The Toxicogenetics of Antirretroviral Therapy: The Evil Inside‏
670 ‎‡a Author's Tolerability of Current Antiretroviral Single-Tablet Regimens‏
670 ‎‡a Author's Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome‏
670 ‎‡a Author's Very low level viraemia and risk of virological failure in treated HIV-1-infected patients‏
670 ‎‡a Author's Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.‏
670 ‎‡a Author's Zinc Alpha -2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs‏
909 ‎‡a (scopus) 35517147900‏ ‎‡9 1‏
909 ‎‡a (orcid) 0000000266926186‏ ‎‡9 1‏
919 ‎‡a norelationshipbetweentnfαgeneticvariantsandcombinationantiretroviraltherapyrelatedlipodystrophysyndromeinhivtype1infectedpatientsacasecontrolstudyandametaanalysis‏ ‎‡A No relationship between TNF-α genetic variants and combination antiretroviral therapy-related lipodystrophy syndrome in HIV type 1-infected patients: a case-control study and a meta-analysis‏ ‎‡9 2‏
919 ‎‡a moreonunusualformsofmeningococcaldiseasesepticpolyarthritis‏ ‎‡A More on unusual forms of meningococcal disease: septic polyarthritis‏ ‎‡9 1‏
919 ‎‡a moreonadultspontaneouspneumomediastinum‏ ‎‡A More on Adult Spontaneous Pneumomediastinum‏ ‎‡9 1‏
919 ‎‡a mitochondrialandapoptoticinvitromodellingofdifferentialhiv1progressionandantiretroviraltoxicity‏ ‎‡A Mitochondrial and apoptotic in vitro modelling of differential HIV-1 progression and antiretroviral toxicity‏ ‎‡9 1‏
919 ‎‡a lmnamessengerrnaexpressioninhighlyactiveantiretroviraltherapytreatedhivpositivepatients‏ ‎‡A LMNA messenger RNA expression in highly active antiretroviral therapy-treated HIV-positive patients‏ ‎‡9 1‏
919 ‎‡a lipodystrophyandinsulinresistanceincombinationantiretroviraltreatedhiv1infectedpatientsimplicationofresistin‏ ‎‡A Lipodystrophy and Insulin Resistance in Combination Antiretroviral Treated HIV-1–Infected Patients: Implication of Resistin‏ ‎‡9 1‏
919 ‎‡a leptinandadiponectinbutnotil18arerelatedwithinsulinresistanceintreatedhiv1infectedpatientswithlipodystrophy‏ ‎‡A Leptin and adiponectin, but not IL18, are related with insulin resistance in treated HIV-1-infected patients with lipodystrophy‏ ‎‡9 1‏
919 ‎‡a lackofassociationofsdf13avariantallelewithlongtermnonprogressivehiv1infectionisextendedbeyond16years‏ ‎‡A Lack of Association of SDF-1 3???A Variant Allele With Long-Term Nonprogressive HIV-1 Infection Is Extended Beyond 16 Years‏ ‎‡9 1‏
919 ‎‡a involvementofthelpslpbcd14md2tlr4inflammationpathwayinhiv1haartassociatedlipodystrophysyndromehals‏ ‎‡A Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS).‏ ‎‡9 1‏
919 ‎‡a involvementofthelpslpbcd14md2tlr4inflammationpathwayinhiv1haartassociatedlipodystrophysyndrome‏ ‎‡A Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome‏ ‎‡9 1‏
919 ‎‡a influenceofchronicalcoholabuseandliverdiseaseonhepaticaldehydedehydrogenaseactivity‏ ‎‡A Influence of chronic alcohol abuse and liver disease on hepatic aldehyde dehydrogenase activity‏ ‎‡9 1‏
919 ‎‡a inductiontherapywithtrizivirplusefavirenzorlopinavirritonavirfollowedbytriziviraloneinnaivehiv1infectedadults‏ ‎‡A Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults‏ ‎‡9 1‏
919 ‎‡a increasedcholesterolabsorptionratherthansynthesisisinvolvedinboostedproteaseinhibitorassociatedhypercholesterolaemia‏ ‎‡A Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor associated hypercholesterolaemia.‏ ‎‡9 1‏
919 ‎‡a incidenceandriskfactorsofaidsdefiningcancersinacohortofhivpositiveadultsimportanceofthedefinitionofincidentcases‏ ‎‡A Incidence and risk factors of AIDS-defining cancers in a cohort of HIV-positive adults: Importance of the definition of incident cases‏ ‎‡9 1‏
919 ‎‡a invitrocytotoxicityandmitochondrialtoxicityoftenofoviraloneandincombinationwithotherantiretroviralsinhumanrenalproximaltubulecells‏ ‎‡A In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells‏ ‎‡9 1‏
919 ‎‡a immunecorrelatesofnaturalhivelitecontrolandsimultaneoushcvclearancesupercontrollers‏ ‎‡A Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance-Supercontrollers‏ ‎‡9 1‏
919 ‎‡a ifnl4ss469415590polymorphismisassociatedwithunfavourableclinicalandimmunologicalstatusinhivinfectedindividuals‏ ‎‡A IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals.‏ ‎‡9 1‏
919 ‎‡a hlab57andifnl4relatedpolymorphismsareassociatedwithprotectionagainsthiv1diseaseprogressionincontrollers‏ ‎‡A HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers‏ ‎‡9 1‏
919 ‎‡a hivinfectedsubjectswithpoorcd4tcellrecoverydespiteeffectivetherapyexpresshighlevelsofox40andα4β7oncd4tcellspriortherapyinitiation‏ ‎‡A HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation‏ ‎‡9 1‏
919 ‎‡a hivantiretroviraltherapyrelatedlipodystrophysyndromehalsisassociatedwithhigherrbp4andloweromentininplasma‏ ‎‡A HIV/antiretroviral therapy-related lipodystrophy syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma.‏ ‎‡9 1‏
919 ‎‡a hiv1infectioninsubjectsolderthan70amulticentercrosssectionalassessmentincataloniaspain‏ ‎‡A HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain‏ ‎‡9 1‏
919 ‎‡a hiv1haartrelatedlipodystrophysyndromehalsisassociatedwithdecreasedcirculatingstweaklevels‏ ‎‡A HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels‏ ‎‡9 1‏
919 ‎‡a higherlevelsofil6cd4turnoverandtregfrequencyarealreadypresentbeforecartinhivinfectedsubjectswithlaterlowcd4recovery‏ ‎‡A Higher levels of IL-6, CD4 turnover and Treg frequency are already present before cART in HIV-infected subjects with later low CD4 recovery.‏ ‎‡9 1‏
919 ‎‡a highfgf21levelsareassociatedwithalteredbonehomeostasisinhiv1infectedpatients‏ ‎‡A High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients‏ ‎‡9 1‏
919 ‎‡a hbvprimarydrugresistanceinnewlydiagnosedhivhbvcoinfectedindividualsinspain‏ ‎‡A HBV primary drug resistance in newly diagnosed HIV–HBV-coinfected individuals in Spain‏ ‎‡9 1‏
919 ‎‡a glutaminolysisandlipoproteinsarekeyfactorsinlateimmunerecoveryinsuccessfullytreatedhivinfectedpatients‏ ‎‡A Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients‏ ‎‡9 1‏
919 ‎‡a geneticpolymorphismsofadh2adh3cyp4502e1dra1andpst1andaldh2inspanishmenlackofassociationwithalcoholismandalcoholicliverdisease‏ ‎‡A Genetic polymorphisms of ADH2, ADH3, CYP4502E1 Dra-I and Pst-I, and ALDH2 in Spanish men: lack of association with alcoholism and alcoholic liver disease.‏ ‎‡9 1‏
919 ‎‡a geneticandfunctionalmitochondrialassessmentofhivinfectedpatientsdevelopinghaartrelatedhyperlactatemia‏ ‎‡A Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemia‏ ‎‡9 1‏
919 ‎‡a 1lineantiretroviraltherapywithefavirenzorlopinavirritonavirplus2nucleosideanaloguesthesuskastudyanonrandomizedcomparisonfromthevachcohort‏ ‎‡A First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort‏ ‎‡9 1‏
919 ‎‡a factorsleadingtothelossofnaturalelitecontrolofhiv1infection‏ ‎‡A Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.‏ ‎‡9 1‏
919 ‎‡a executivesummaryofthegesidanationalaidsplanconsensusdocumentonantiretroviraltherapyinadultsinfectedbythehumanimmunodeficiencyvirusupdatedjanuary‏ ‎‡A Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).‏ ‎‡9 1‏
919 ‎‡a evaluationofthepharmacogeneticsofimmunerecoveryintreatedhivinfectedpatients‏ ‎‡A Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients‏ ‎‡9 1‏
919 ‎‡a epidemiologyandoutcomeofpseudomonasaeruginosabacteremiawithspecialemphasisontheinfluenceofantibiotictreatmentanalysisof189episodes‏ ‎‡A Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes‏ ‎‡9 1‏
919 ‎‡a epidemiologyandclinicalmanifestationsofinfectionduetonocardiaspeciesintarragona19972008nocardiacyriacigeorgicaisanemergingpathogen‏ ‎‡A Epidemiology and clinical manifestations of infection due to Nocardia species in Tarragona, 1997-2008: Nocardia cyriacigeorgica is an emerging pathogen‏ ‎‡9 1‏
919 ‎‡a efficacyandsafetyofswitchingfromboostedlopinavirtoboostedatazanavirinpatientswithvirologicalsuppressionreceivingalpvrcontaininghaarttheatazipstudy‏ ‎‡A Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.‏ ‎‡9 1‏
919 ‎‡a effectsofdocosahexanoicacidsupplementationoninflammatoryandsubcutaneousadiposetissuegeneexpressioninhivinfectedpatientsoncombinationantiretroviraltherapycartasubstudyofarandomizeddoubleblindplacebocontrolledstudy‏ ‎‡A Effects of docosahexanoic acid supplementation on inflammatory and subcutaneous adipose tissue gene expression in HIV-infected patients on combination antiretroviral therapy (cART). A sub-study of a randomized, double-blind, placebo-controlled study‏ ‎‡9 1‏
919 ‎‡a effectsofdocosahexanoicacidonmetabolicandfatparametersinhivinfectedpatientsoncartarandomizeddoubleblindplacebocontrolledstudy‏ ‎‡A Effects of docosahexanoic acid on metabolic and fat parameters in HIV-infected patients on cART: A randomized, double-blind, placebo-controlled study‏ ‎‡9 1‏
919 ‎‡a effectivenessandsafetyofdidanosinelamivudineandefavirenzversuszidovudinelamivudineandefavirenzfortheinitialtreatmentofhivinfectedpatientsfromthespanishvachcohort‏ ‎‡A Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort‏ ‎‡9 1‏
919 ‎‡a effectoftnf Alpha geneticvariantsandccr5delta32onthevulnerabilitytohiv1infectionanddiseaseprogressionincaucasianspaniards‏ ‎‡A Effect of TNF- Alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards‏ ‎‡9 1‏
919 ‎‡a effectofgeneticvariantsofccr2andccl2onthenaturalhistoryofhiv1infectionccl22518ggisoverrepresentedinacohortofspanishhiv1infectedsubjects‏ ‎‡A Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects.‏ ‎‡9 1‏
919 ‎‡a dyslipidaemiainhivinfectedwomenonantiretroviraltherapyanalysisof922patientsfromthespanishvachcohort‏ ‎‡A Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.‏ ‎‡9 1‏
919 ‎‡a drugtherapiesforhivrelatedmetabolicdisorders‏ ‎‡A Drug therapies for HIV-related metabolic disorders.‏ ‎‡9 1‏
919 ‎‡a drugsafetyprofileofintegrasestrandtransferinhibitors‏ ‎‡A Drug safety profile of integrase strand transfer inhibitors.‏ ‎‡9 1‏
919 ‎‡a drugsafetyevaluationprofileofstavudinepluslamivudineforhiv1aidsinfection‏ ‎‡A Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection‏ ‎‡9 1‏
919 ‎‡a doalcoholmetabolizingenzymegenepolymorphismsincreasetheriskofalcoholismandalcoholicliverdisease‏ ‎‡A Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease?‏ ‎‡9 1‏
919 ‎‡a differentialsubcutaneousadiposetissuegeneexpressionpatternsinarandomizedclinicaltrialofefavirenzorlopinavirritonavirinantiretroviralnaivepatients‏ ‎‡A Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients.‏ ‎‡9 1‏
919 ‎‡a diagnosisofhepatichydrothoraxintheabsenceofascitesbyintraperitonealinjectionof99mtcfluorcolloid‏ ‎‡A Diagnosis of hepatic hydrothorax in the absence of ascites by intraperitoneal injection of 99m-Tc-Fluor colloid‏ ‎‡9 1‏
919 ‎‡a delayintheinitiationofhaartpoorervirologicalresponseandhighermortalityamonghivinfectedinjectingdrugusersinspain‏ ‎‡A Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.‏ ‎‡9 1‏
919 ‎‡a cutaneouspolyarteritisnodosainhumanimmunodeficiencyvirusinfection‏ ‎‡A Cutaneous polyarteritis nodosa in human immunodeficiency virus infection.‏ ‎‡9 1‏
919 ‎‡a currentsituationofthepharmacogeneticsofimmunerecoveryintreatedhivinfectedpatients‏ ‎‡A Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients‏ ‎‡9 1‏
919 ‎‡a correlationofthevirologicalresponsetoshorttermmaravirocmonotherapywithstandardanddeepsequencingbasedgenotypictropismpredictionmethods‏ ‎‡A Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.‏ ‎‡9 1‏
919 ‎‡a contributionofoxidativestresstononaidseventsinhivinfectedpatients‏ ‎‡A Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients‏ ‎‡9 1‏
919 ‎‡a combinationantiretroviraltherapy‏ ‎‡A Combination antiretroviral therapy.‏ ‎‡9 1‏
919 ‎‡a clinicaloutcomeofhivinfectedpatientswithsustainedvirologicresponsetoantiretroviraltherapylongtermfollowupofamulticentercohort‏ ‎‡A Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort‏ ‎‡9 1‏
919 ‎‡a clinicalcharacterizationofbreakthroughbacteraemiaasurveyof392episodes‏ ‎‡A Clinical characterization of breakthrough bacteraemia: a survey of 392 episodes.‏ ‎‡9 1‏
919 ‎‡a circulatingmetabolomicprofilecanpredictdyslipidemiainhivpatientsundergoingantiretroviraltherapy‏ ‎‡A Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy‏ ‎‡9 1‏
919 ‎‡a circulatingfibroblastgrowthfactor23fgf23levelsareassociatedwithmetabolicdisturbancesandfatdistributionbutnotcardiovascularriskinhivinfectedpatients‏ ‎‡A Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients‏ ‎‡9 1‏
919 ‎‡a characteristicsandoutcomeofhivinfectioningypsiesinthespanishvachcohort‏ ‎‡A Characteristics and outcome of HIV infection in gypsies in the Spanish VACH Cohort‏ ‎‡9 1‏
919 ‎‡a cerebralpneumocystiscariniiinfectioninaids‏ ‎‡A Cerebral Pneumocystis carinii infection in AIDS.‏ ‎‡9 1‏
919 ‎‡a centralnervoussystempneumocystosisinaidsantemortemdiagnosisandsuccessfultreatment‏ ‎‡A Central Nervous System Pneumocystosis in AIDS: Antemortem Diagnosis and Successful Treatment‏ ‎‡9 1‏
919 ‎‡a caracteristicasclinicasyevoluciondelaendocarditisinfecciosaenunapoblaciongeneralnoseleccionadaatendidaen1hospitaldocentequenodisponedecirugiacardiacaestudiode120casos‏ ‎‡A Características clínicas y evolución de la endocarditis infecciosa en una población general no seleccionada, atendida en un hospital docente que no dispone de cirugía cardiaca. Estudio de 120 casos‏ ‎‡9 1‏
919 ‎‡a bacterialmeningitisinhiv1infectedpatientsintheeraofhighlyactiveantiretroviraltherapy‏ ‎‡A Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy‏ ‎‡9 1‏
919 ‎‡a bacteraemiainadultsduetoglucosenonfermentativegramnegativebacilliotherthanpaeruginosa‏ ‎‡A Bacteraemia in adults due to glucose non-fermentative Gram-negative bacilli other than P. aeruginosa‏ ‎‡9 1‏
919 ‎‡a atypicalliveralcoholdehydrogenaseinthespanishpopulationitsrelationwiththedevelopmentofalcoholicliverdisease‏ ‎‡A Atypical liver alcohol dehydrogenase in the Spanish population: its relation with the development of alcoholic liver disease‏ ‎‡9 1‏
919 ‎‡a atazanavirdosereduction1sizedoesnotfitall‏ ‎‡A Atazanavir dose reduction: one size does not fit all.‏ ‎‡9 1‏
919 ‎‡a associationofthymidylatesynthasepolymorphismswithacutepancreatitisandorperipheralneuropathyinhivinfectedpatientsonstavudinebasedtherapy‏ ‎‡A Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapy‏ ‎‡9 1‏
919 ‎‡a associationofthymidylatesynthasegenepolymorphismswithstavudinetriphosphateintracellularlevelsandlipodystrophy‏ ‎‡A Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy‏ ‎‡9 1‏
919 ‎‡a associationofpatientsgeographicoriginswithviralhepatitiscoinfectionpatternsspain‏ ‎‡A Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain.‏ ‎‡9 1‏
919 ‎‡a associationofitpagenepolymorphismsandtheriskofribavirininducedanemiainhivhepatitis100virushcvcoinfectedpatientsreceivinghcvcombinationtherapy‏ ‎‡A Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.‏ ‎‡9 1‏
919 ‎‡a artregimesandfatthehealinghandwieldingthesword‏ ‎‡A ART regimes and fat: the healing hand wielding the sword.‏ ‎‡9 1‏
919 ‎‡a antiretroviraltherapyinterruptionguidedbycd4cellcountsandplasmahiv1rnalevelsinchronicallyhiv1infectedpatients‏ ‎‡A Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.‏ ‎‡9 1‏
919 ‎‡a updateonthepharmacologicalstrategiesinthetreatmentofhiv1associatedadiposeredistributionsyndromes‏ ‎‡A An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes‏ ‎‡9 1‏
919 ‎‡a unusualpresentationofsecondarypleuralhydatidosis‏ ‎‡A An unusual presentation of secondary pleural hydatidosis‏ ‎‡9 1‏
919 ‎‡a alcoholdehydrogenaseofhumanandratbloodvesselsroleinethanolmetabolism‏ ‎‡A Alcohol dehydrogenase of human and rat blood vessels. Role in ethanol metabolism.‏ ‎‡9 1‏
919 ‎‡a adipogeniclipidinflammatoryandmitochondrialparametersinsubcutaneousadiposetissueofuntreatedhiv1infectedlongtermnonprogressors‏ ‎‡A Adipogenic/Lipid, Inflammatory, and Mitochondrial Parameters in Subcutaneous Adipose Tissue of Untreated HIV-1–Infected Long-Term Nonprogressors‏ ‎‡9 1‏
919 ‎‡a absenceofcxcr4100terminalpolymorphismsinhiv1infectedanduninfectedspaniards‏ ‎‡A Absence of CXCR4 C-terminal polymorphisms in HIV-1-infected and uninfected Spaniards.‏ ‎‡9 1‏
919 ‎‡a studyonthetnfαsystemincaucasianspanishpatientswithalcoholicliverdisease‏ ‎‡A A study on the TNF-α system in Caucasian Spanish patients with alcoholic liver disease‏ ‎‡9 1‏
919 ‎‡a studyoffattyacidbindingprotein4inhiv1infectionandincombinationantiretroviraltherapyrelatedmetabolicdisturbancesandlipodystrophy‏ ‎‡A A study of fatty acid binding protein 4 in HIV-1 infection and in combination antiretroviral therapy-related metabolic disturbances and lipodystrophy‏ ‎‡9 1‏
919 ‎‡a randomizedtrialcomparingtheefficacyandtolerabilityof2haartstrategiesat2yearsinantiretroviralnaivepatients‏ ‎‡A A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients‏ ‎‡9 1‏
919 ‎‡a lowerbaselinecd4cd8tcellratioisindependentlyassociatedwithimmunodiscordantresponsetoantiretroviraltherapyinhivinfectedsubjects‏ ‎‡A A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects.‏ ‎‡9 1‏
919 ‎‡a baselinemetabolomicsignatureisassociatedwithimmunologicalcd4+tcellrecoveryafter36monthsofartinhivinfectedpatients‏ ‎‡A A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of ART in HIV-infected patients.‏ ‎‡9 1‏
919 ‎‡a 48weekstudyoffatmolecularalterationsinhivnaivepatientsstartingtenofoviremtricitabinewithlopinavirritonavirorefavirenz‏ ‎‡A A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz‏ ‎‡9 1‏
919 ‎‡a zinc Alpha 2glycoproteinisimplicatedindyslipidaemiainhiv1infectedpatientstreatedwithantiretroviraldrugs‏ ‎‡A Zinc Alpha -2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs‏ ‎‡9 1‏
919 ‎‡a virologicalresponseaftershorttermccr5antagonistexposureinhivinfectedpatientsfrequencyofsubjectswithvirologicalresponseandassociatedfactors‏ ‎‡A Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.‏ ‎‡9 1‏
919 ‎‡a verylowlevelviraemiaandriskofvirologicalfailureintreatedhiv1infectedpatients‏ ‎‡A Very low level viraemia and risk of virological failure in treated HIV-1-infected patients‏ ‎‡9 1‏
919 ‎‡a uridinemetabolisminhiv1infectedpatientseffectofinfectionofantiretroviraltherapyandofhiv1artassociatedlipodystrophysyndrome‏ ‎‡A Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome‏ ‎‡9 1‏
919 ‎‡a tolerabilityofcurrentantiretroviralsingletabletregimens‏ ‎‡A Tolerability of Current Antiretroviral Single-Tablet Regimens‏ ‎‡9 1‏
919 ‎‡a toxicogeneticsofantirretroviraltherapytheevilinside‏ ‎‡A The Toxicogenetics of Antirretroviral Therapy: The Evil Inside‏ ‎‡9 1‏
919 ‎‡a toxicogeneticsofantiretroviraltherapytheevilinside‏ ‎‡A The toxicogenetics of antiretroviral therapy: the evil inside‏ ‎‡9 1‏
919 ‎‡a relationshipbetweenantiretroviralprescriptionpatternsandtreatmentguidelinesintreatmentnaivehiv1infectedpatients‏ ‎‡A The relationship between antiretroviral prescription patterns and treatment guidelines in treatment-naïve HIV-1-infected patients‏ ‎‡9 1‏
919 ‎‡a il6systeminhiv1infectionandinhaartrelatedfatredistributionsyndromes‏ ‎‡A The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromes‏ ‎‡9 1‏
919 ‎‡a twavealternansassociatedwithamiodarone‏ ‎‡A T wave alternans associated with amiodarone‏ ‎‡9 1‏
919 ‎‡a switchingantiretroviralregimesforthetreatmentofhivsafetyimplications‏ ‎‡A Switching antiretroviral regimes for the treatment of HIV: safety implications‏ ‎‡9 1‏
919 ‎‡a stavudineextendedrelease11dailybristolmyerssquibbforthetreatmentofhivaids‏ ‎‡A Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS.‏ ‎‡9 1‏
919 ‎‡a spermatozoafromnormozoospermicfertileandinfertileindividualsconveyadistinctmirnacargo‏ ‎‡A Spermatozoa from normozoospermic fertile and infertile individuals convey a distinct miRNA cargo.‏ ‎‡9 1‏
919 ‎‡a spanishhiv1infectedlongtermnonprogressorsofmorethan15yearshaveanincreasedfrequencyofthecx3cr1249ivariantallele‏ ‎‡A Spanish HIV-1-Infected Long-Term Nonprogressors of More Than 15 Years Have an Increased Frequency of the CX3CR1 249I Variant Allele‏ ‎‡9 1‏
919 ‎‡a serumfgf21levelsareelevatedinassociationwithlipodystrophyinsulinresistanceandbiomarkersofliverinjuryinhiv1infectedpatients‏ ‎‡A Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients‏ ‎‡9 1‏
919 ‎‡a sarcoidosispresentingasmultiplepulmonarynodulesandnephroticsyndrome‏ ‎‡A Sarcoidosis presenting as multiple pulmonary nodules and nephrotic syndrome.‏ ‎‡9 1‏
919 ‎‡a riskfactorscd4longtermevolutionandmortalityofhivinfectedpatientswhopersistentlymaintainlowcd4countsdespitevirologicalresponsetohaart‏ ‎‡A Risk Factors, CD4 Long-Term Evolution and Mortality of HIV-Infected Patients who Persistently Maintain Low CD4 Counts, Despite Virological Response to HAART‏ ‎‡9 1‏
919 ‎‡a relationshipbetweenhivhighlyactiveantiretroviraltherapyhaartassociatedlipodystrophysyndromeandstavudinetriphosphateintracellularlevelsinpatientswithstavudinebasedantiretroviralregimens‏ ‎‡A Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens‏ ‎‡9 1‏
919 ‎‡a relationshipbetweenhivhighlyactiveantiretroviraltherapy‏ ‎‡A Relationship between HIV/Highly active antiretroviral therapy‏ ‎‡9 1‏
919 ‎‡a reducedlevelsofserumfgf19andimpairedexpressionofreceptorsforendocrinefgfsinadiposetissuefromhivinfectedpatients‏ ‎‡A Reduced levels of serum FGF19 and impaired expression of receptors for endocrine FGFs in adipose tissue from HIV-infected patients.‏ ‎‡9 1‏
919 ‎‡a recurrentpericarditisandcardiactamponadeinrheumatoidarthritiseffectivenessofcolchicine‏ ‎‡A Recurrent Pericarditis and Cardiac Tamponade in Rheumatoid Arthritis: Effectiveness of Colchicine‏ ‎‡9 1‏
919 ‎‡a randomizedtrialcomparingpegylatedinterferon Alpha 2bversuspegylatedinterferon Alpha 2abothplusribavirintotreatchronichepatitis100inhumanimmunodeficiencyviruspatients‏ ‎‡A Randomized trial comparing pegylated interferon Alpha -2b versus pegylated interferon Alpha -2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients‏ ‎‡9 1‏
919 ‎‡a pyomyositisduetoescherichiacoliinapatientinfectedbyhiv‏ ‎‡A Pyomyositis due to Escherichia coli in a patient infected by HIV.‏ ‎‡9 1‏
919 ‎‡a pseudomonasaeruginosabacteremiainpatientsinfectedwithhumanimmunodeficiencyvirustype1‏ ‎‡A Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1.‏ ‎‡9 1‏
919 ‎‡a proximaltubularkidneydamageandtenofoviraroleformitochondrialtoxicity‏ ‎‡A Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?‏ ‎‡9 1‏
919 ‎‡a proteomicprofileassociatedwithlossofspontaneoushiv1elitecontrol‏ ‎‡A Proteomic Profile Associated with Loss of Spontaneous HIV-1 Elite Control‏ ‎‡9 1‏
919 ‎‡a previousciprofloxacinexposureisassociatedwithresistancetobetalactamantibioticsinsubsequentpseudomonasaeruginosabacteremicisolates‏ ‎‡A Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.‏ ‎‡9 1‏
919 ‎‡a predictionoflongtermoutcomesofhivinfectedpatientsdevelopingnonaidseventsusingamultistateapproach‏ ‎‡A Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach‏ ‎‡9 1‏
919 ‎‡a polymorphismsofpyrimidinepathwayenzymesencodinggenesandhlab4001carriageinstavudineassociatedlipodystrophyinhivinfectedpatients‏ ‎‡A Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40∶01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients‏ ‎‡9 1‏
919 ‎‡a polymorphismsofalcoholmetabolizingenzymesandtheriskforalcoholismandalcoholicliverdiseaseincaucasianspanishwomen‏ ‎‡A Polymorphisms of alcohol-metabolizing enzymes and the risk for alcoholism and alcoholic liver disease in Caucasian Spanish women‏ ‎‡9 1‏
919 ‎‡a polymorphismsintheinterleukin10genepromoterandtheriskofalcoholismandalcoholicliverdiseaseincaucasianspaniardmen‏ ‎‡A Polymorphisms in the interleukin-10 gene promoter and the risk of alcoholism and alcoholic liver disease in Caucasian Spaniard men.‏ ‎‡9 1‏
919 ‎‡a polymorphismsinthe3untranslatedregionofthefractalkinecx3cl1geneandtheriskofhiv1infectionanddiseaseprogression‏ ‎‡A Polymorphisms in the 3′ untranslated region of the fractalkine (CX3CL1) gene and the risk of HIV-1 infection and disease progression‏ ‎‡9 1‏
919 ‎‡a polymorphismsinthe3untranslatedregionofthefractalkine‏ ‎‡A Polymorphisms in the 3′ untranslated region of the fractalkine‏ ‎‡9 1‏
919 ‎‡a polymorphismofranteschemokinegenepromoterisnotassociatedwithlongtermnonprogressivehiv1infectionofmorethan16years‏ ‎‡A Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years.‏ ‎‡9 1‏
919 ‎‡a pneumocystisjiroveciipneumoniainspanishhivinfectedpatientsinthecombinedantiretroviraltherapyeraprevalenceofdihydropteroatesynthasemutationsandprognosticfactorsofmortality‏ ‎‡A Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality‏ ‎‡9 1‏
919 ‎‡a pharmacogeneticsofthelipodystrophysyndromeassociatedwithhivinfectionandcombinationantiretroviraltherapy‏ ‎‡A Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.‏ ‎‡9 1‏
919 ‎‡a pharmacogeneticsofefficacyandsafetyofhcvtreatmentinhcvhivcoinfectedpatientssignificantassociationswithil28bandsocs3genevariants‏ ‎‡A Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants‏ ‎‡9 1‏
919 ‎‡a patientscharacteristicsandclinicalimplicationsofsuboptimalcd4tcellgainsafter1yearofsuccessfulantiretroviraltherapy‏ ‎‡A Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy‏ ‎‡9 1‏
943 ‎‡a 201x‏ ‎‡A 2014‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 ISNI|000000006873196X‏
996 ‎‡2 BNE|XX5251014‏
996 ‎‡2 ISNI|0000000423397944‏
996 ‎‡2 DNB|1056640626‏
996 ‎‡2 BIBSYS|13014033‏
996 ‎‡2 BNE|XX6509101‏
996 ‎‡2 BNC|981058512961006706‏
996 ‎‡2 BIBSYS|8076922‏
996 ‎‡2 ISNI|0000000082336464‏
996 ‎‡2 ISNI|000000041002468X‏
996 ‎‡2 LC|n 50051573‏
996 ‎‡2 ISNI|0000000444595018‏
996 ‎‡2 LC|no2021154588‏
996 ‎‡2 BNF|16777907‏
996 ‎‡2 SUDOC|178068683‏
996 ‎‡2 ISNI|0000000358684006‏
996 ‎‡2 BNC|981058612648106706‏
996 ‎‡2 BNC|981061162863506706‏
996 ‎‡2 BNE|XX5888495‏
996 ‎‡2 ISNI|0000000140473273‏
996 ‎‡2 NUKAT|n 2018245461‏
996 ‎‡2 BNE|XX863487‏
996 ‎‡2 BNE|XX5619752‏
996 ‎‡2 BNC|981058611766006706‏
996 ‎‡2 BNE|XX1347152‏
996 ‎‡2 BNE|XX1319648‏
996 ‎‡2 SUDOC|231952856‏
996 ‎‡2 LC|no2021013793‏
996 ‎‡2 PTBNP|142401‏
996 ‎‡2 DNB|1016264496‏
996 ‎‡2 BNE|XX1370250‏
996 ‎‡2 NTA|246905379‏
996 ‎‡2 BNE|XX1100306‏
996 ‎‡2 BNCHL|10000000000000000174842‏
996 ‎‡2 BNE|XX1480406‏
996 ‎‡2 LC|n 95111174‏
996 ‎‡2 DNB|171337182‏
996 ‎‡2 RERO|A009371130‏
996 ‎‡2 BAV|495_39860‏
996 ‎‡2 SUDOC|110922034‏
996 ‎‡2 BAV|495_39859‏
996 ‎‡2 ISNI|0000000031087592‏
996 ‎‡2 BLBNB|000381990‏
996 ‎‡2 SUDOC|150574118‏
996 ‎‡2 XA|5061‏
996 ‎‡2 BNCHL|10000000000000000081456‏
996 ‎‡2 BNF|13542159‏
996 ‎‡2 SUDOC|09414849X‏
996 ‎‡2 ISNI|0000000369478478‏
996 ‎‡2 LC|n 2005204237‏
996 ‎‡2 BNF|17898500‏
996 ‎‡2 LC|nr 99025524‏
996 ‎‡2 BNE|XX984442‏
996 ‎‡2 DNB|1057622478‏
996 ‎‡2 SUDOC|079702279‏
996 ‎‡2 BNC|981058513139006706‏
996 ‎‡2 BNCHL|10000000000000000127600‏
996 ‎‡2 BLBNB|001023373‏
996 ‎‡2 ISNI|000000005952968X‏
996 ‎‡2 BNCHL|10000000000000000012015‏
996 ‎‡2 BNE|XX862899‏
996 ‎‡2 BNE|XX1441457‏
996 ‎‡2 BNC|981058615965706706‏
996 ‎‡2 ISNI|0000000047825131‏
996 ‎‡2 LC|n 2006006114‏
996 ‎‡2 BNF|12529179‏
996 ‎‡2 BNC|981058516624806706‏
996 ‎‡2 NTA|135554357‏
996 ‎‡2 BNC|981058527265806706‏
996 ‎‡2 ISNI|0000000072459604‏
996 ‎‡2 BNC|981058509735406706‏
996 ‎‡2 SUDOC|111171881‏
996 ‎‡2 BNE|XX1605573‏
996 ‎‡2 LC|n 87118899‏
996 ‎‡2 BNE|XX1577232‏
996 ‎‡2 BNC|981058511176206706‏
996 ‎‡2 LC|no2019111151‏
996 ‎‡2 BNE|XX872270‏
996 ‎‡2 SUDOC|070183422‏
996 ‎‡2 LC|n 2005015250‏
996 ‎‡2 SUDOC|068719396‏
996 ‎‡2 JPG|500268360‏
996 ‎‡2 BNE|XX1039834‏
996 ‎‡2 DNB|120310724‏
996 ‎‡2 BNC|981058524070506706‏
996 ‎‡2 BNE|XX6158434‏
996 ‎‡2 J9U|987007329918905171‏
996 ‎‡2 PTBNP|1012947‏
996 ‎‡2 BNC|981058509715906706‏
996 ‎‡2 RERO|A003073477‏
996 ‎‡2 BNC|981058529401806706‏
996 ‎‡2 BNE|XX1265154‏
996 ‎‡2 BNE|XX895108‏
996 ‎‡2 BNE|XX1408897‏
996 ‎‡2 ISNI|0000000060671616‏
996 ‎‡2 ISNI|0000000034109582‏
996 ‎‡2 BNCHL|10000000000000000287265‏
996 ‎‡2 J9U|987007334809405171‏
996 ‎‡2 NUKAT|n 2017260030‏
996 ‎‡2 JPG|500588646‏
996 ‎‡2 PTBNP|157714‏
996 ‎‡2 BNF|15365678‏
996 ‎‡2 BNE|XX888719‏
996 ‎‡2 DNB|1138941549‏
996 ‎‡2 LC|nb 98039468‏
996 ‎‡2 ISNI|0000000394723068‏
996 ‎‡2 BNE|XX1709427‏
996 ‎‡2 BNE|XX1639437‏
996 ‎‡2 BNE|XX993632‏
996 ‎‡2 BNE|XX1578568‏
996 ‎‡2 BNCHL|10000000000000000862468‏
996 ‎‡2 BNC|981058616518606706‏
996 ‎‡2 LC|n 2004039357‏
996 ‎‡2 BNE|XX1100815‏
996 ‎‡2 BNE|XX1181562‏
996 ‎‡2 BLBNB|000529505‏
996 ‎‡2 BNE|XX5194511‏
996 ‎‡2 LC|no2009182335‏
996 ‎‡2 BIBSYS|90369731‏
996 ‎‡2 SUDOC|223876267‏
996 ‎‡2 SUDOC|174451032‏
996 ‎‡2 BNE|XX904592‏
996 ‎‡2 LC|no2011017730‏
996 ‎‡2 ISNI|0000000037895857‏
996 ‎‡2 BNC|981058518485306706‏
996 ‎‡2 RERO|A022598019‏
996 ‎‡2 LC|n 2001129196‏
996 ‎‡2 BNE|XX1480307‏
996 ‎‡2 NII|DA15281129‏
996 ‎‡2 ISNI|0000000060887695‏
996 ‎‡2 RERO|A025069840‏
996 ‎‡2 SUDOC|13541217X‏
996 ‎‡2 SUDOC|155281372‏
996 ‎‡2 PLWABN|9810674026505606‏
996 ‎‡2 SUDOC|195577779‏
996 ‎‡2 BNC|981058509930106706‏
996 ‎‡2 JPG|500708549‏
996 ‎‡2 SUDOC|125243588‏
996 ‎‡2 DNB|119247674‏
996 ‎‡2 LC|nb2017000912‏
996 ‎‡2 ISNI|0000000435011383‏
996 ‎‡2 LC|no2014022926‏
996 ‎‡2 RERO|A003941013‏
996 ‎‡2 BNC|981058525814806706‏
996 ‎‡2 DNB|1027782418‏
996 ‎‡2 ISNI|0000000115768221‏
996 ‎‡2 LC|n 2001095784‏
996 ‎‡2 BNCHL|10000000000000000173486‏
996 ‎‡2 ISNI|0000000037106686‏
996 ‎‡2 LC|n 84055934‏
996 ‎‡2 DNB|1042010722‏
996 ‎‡2 ISNI|0000000496458736‏
996 ‎‡2 BNE|XX1306315‏
996 ‎‡2 ISNI|0000000039418296‏
996 ‎‡2 LC|no2007049651‏
996 ‎‡2 BNC|981058519868206706‏
996 ‎‡2 BNCHL|10000000000000000173489‏
996 ‎‡2 PTBNP|146539‏
996 ‎‡2 ISNI|0000000372668096‏
996 ‎‡2 ISNI|000000006075637X‏
996 ‎‡2 BNC|981058510329606706‏
996 ‎‡2 BNCHL|10000000000000000127601‏
996 ‎‡2 BNC|981058516117906706‏
996 ‎‡2 BNCHL|10000000000000000212606‏
996 ‎‡2 ISNI|0000000399766913‏
996 ‎‡2 LC|n 88093123‏
996 ‎‡2 SUDOC|079584969‏
996 ‎‡2 ISNI|0000000070517444‏
996 ‎‡2 BNCHL|10000000000000000258625‏
996 ‎‡2 BNCHL|10000000000000000051922‏
996 ‎‡2 ISNI|0000000070919363‏
996 ‎‡2 NYNYRILM|385762‏
996 ‎‡2 BNE|XX1480316‏
996 ‎‡2 ISNI|0000000398347899‏
996 ‎‡2 ISNI|0000000060067806‏
996 ‎‡2 SUDOC|17231190X‏
996 ‎‡2 SUDOC|199457778‏
996 ‎‡2 SUDOC|070670757‏
996 ‎‡2 LC|no2019009319‏
996 ‎‡2 SUDOC|106550241‏
996 ‎‡2 CAOONL|ncf11184257‏
996 ‎‡2 LC|no2009197715‏
996 ‎‡2 ISNI|0000000119444486‏
996 ‎‡2 BNE|XX1079131‏
996 ‎‡2 ISNI|0000000107989737‏
996 ‎‡2 BNE|XX1258083‏
996 ‎‡2 BNE|XX5002010‏
996 ‎‡2 BAV|495_285820‏
996 ‎‡2 ISNI|0000000066387456‏
996 ‎‡2 ISNI|0000000048862890‏
996 ‎‡2 DNB|142843598‏
996 ‎‡2 BNCHL|10000000000000000118184‏
996 ‎‡2 ISNI|0000000083951936‏
996 ‎‡2 LC|no2011067169‏
996 ‎‡2 BNE|XX1464671‏
996 ‎‡2 NYNYRILM|30561‏
996 ‎‡2 SUDOC|236422081‏
996 ‎‡2 BNE|XX1480242‏
996 ‎‡2 EGAXA|Balis310746878‏
996 ‎‡2 BNE|XX1515203‏
996 ‎‡2 PTBNP|1785580‏
996 ‎‡2 ARBABN|000031465‏
996 ‎‡2 BNE|XX851662‏
996 ‎‡2 ISNI|000000005936247X‏
996 ‎‡2 BNC|981058608907106706‏
996 ‎‡2 LC|n 50053149‏
996 ‎‡2 BNC|981058520203306706‏
996 ‎‡2 BNCHL|10000000000000000800784‏
996 ‎‡2 SUDOC|034546979‏
996 ‎‡2 DNB|1157151930‏
996 ‎‡2 ISNI|0000000041244766‏
996 ‎‡2 BNE|XX1017114‏
996 ‎‡2 ISNI|0000000357988550‏
996 ‎‡2 BNC|981058511679606706‏
996 ‎‡2 JPG|500039778‏
996 ‎‡2 RERO|A018646405‏
996 ‎‡2 BNE|XX5400919‏
996 ‎‡2 LC|n 2012212825‏
996 ‎‡2 SUDOC|131930001‏
996 ‎‡2 ISNI|0000000114770207‏
996 ‎‡2 BNE|XX5369990‏
996 ‎‡2 NUKAT|n 2017077755‏
996 ‎‡2 BNC|981058520203806706‏
996 ‎‡2 DNB|126830746‏
996 ‎‡2 LC|n 2022015177‏
996 ‎‡2 PTBNP|1808669‏
996 ‎‡2 NTA|127488960‏
996 ‎‡2 DNB|1056775866‏
996 ‎‡2 J9U|987007272247105171‏
996 ‎‡2 LC|n 2004114516‏
996 ‎‡2 NUKAT|n 2004015464‏
996 ‎‡2 BNE|XX1528891‏
996 ‎‡2 LC|no2022131403‏
996 ‎‡2 ISNI|0000000060751499‏
996 ‎‡2 BNC|981060172578206706‏
996 ‎‡2 BNE|XX1038791‏
996 ‎‡2 LC|no2023010278‏
996 ‎‡2 BNE|XX4689300‏
996 ‎‡2 NSK|000574117‏
996 ‎‡2 LC|n 95110547‏
996 ‎‡2 JPG|500040314‏
996 ‎‡2 DNB|1028084641‏
996 ‎‡2 LC|no2013003134‏
996 ‎‡2 BNC|981058510254006706‏
996 ‎‡2 BNE|XX1688568‏
996 ‎‡2 SZ|119247674‏
996 ‎‡2 BNC|981058614717606706‏
996 ‎‡2 BNE|XX5046050‏
996 ‎‡2 NYNYRILM|54969‏
996 ‎‡2 ISNI|0000000059340713‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏